BriaCell Therapeutics (TSX:BCT) Change In Inventory : C$0.00 Mil (TTM As of Jan. 2024)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Change In Inventory?

BriaCell Therapeutics's change in inventory for the quarter that ended in Jan. 2024 was C$0.00 Mil. It means BriaCell Therapeutics's inventory stayed the same from Oct. 2023 to Jan. 2024 .

BriaCell Therapeutics's change in inventory for the fiscal year that ended in Jul. 2023 was C$0.00 Mil. It means BriaCell Therapeutics's inventory stayed the same from Jul. 2022 to Jul. 2023 .

BriaCell Therapeutics's Total Inventories for the quarter that ended in Jan. 2024 was C$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BriaCell Therapeutics Change In Inventory Historical Data

The historical data trend for BriaCell Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Change In Inventory Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Change In Inventory

Get a 7-Day Free Trial

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

BriaCell Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

BriaCell Therapeutics (TSX:BCT) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BriaCell Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BriaCell Therapeutics's Inventory Turnover for the quarter that ended in Jan. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BriaCell Therapeutics's Inventory to Revenue for the quarter that ended in Jan. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

BriaCell Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (TSX:BCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

BCTX:USA

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko

Director

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines